About FSHD Canada Foundation

FSHD clinical trials are coming to Canada – get registered here: Canadian Neuromuscular Disease Registry

Pre-clinical testing for FSHD CRISPR-inhibition therapy

Pre-clinical testing for FSHD CRISPR-inhibition therapy


  • Amount awarded: AUD $140,419 (Milestone 1)
  • FSHD Canada Foundation Contribution: C$50,000


  • Start Grant: March 1, 2019
  • Milestone 1: by August 31, 2019
  • Milestone 2: by February 28, 2021

Lay Abstract

Principle Investigator: Associate Professor Peter Jones

Research Institution: University of Nevada

CRISPR technology provides an avenue for targeting and correcting virtually any sequence in the human genome, with long-term or permanent beneficial effects. Thus, it has the potential to cure the root cause of a disease such as FSHD, rather than merely treating symptoms. Although typically used for gene editing (in which DNA is cut and replaced, allowing conversion of a disease-causing mutation to the normal sequence), CRISPR can also be used to change the expression level of a disease-causing gene (e.g., CRISPR inhibition turns a gene off) without cutting the genome. FSHD is caused by mis-expression of the DUX4 gene in skeletal muscle, and could potentially be cured by either CRISPR editing or CRISPR inhibition. Because FSHD is associated with highly repetitive DNA sequences, there are a number of concerns with a CRISPR editing approach that introduces many cuts into the genome. CRISPR inhibition circumvents these problems and is a viable approach for FSHD. The goal of this proposal is to test the efficacy, specificity, and stability of this approach in two novel mouse models of FSHD, including a xenograft model that will allow us to study the effects of CRISPR inhibition in human muscle derived from FSHD patient cells.

https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca